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ABSTRACT 
The recent scientific and patented literature concluded that an increased interest in novel dosage forms which retained in the stomach for 
prolong and predictable period of time has been shown. Various technological attempts have been made in the research and development of 
rate controlled oral drug delivery systems to overcome physiological diversities, as short gastric residence times and unpredictable gastric 
emptying times using gastro retentive drug delivery system. The present study attempts to give an insight into the gastro-retentive drug 
delivery systems, and gastric floating dosage forms, in particular. These have attracted the interest of many formulators due to their 
advantages over the conventional drug delivery systems, recently. The study highlights these advantages with reference to the various types 
of gastro retentive drug delivery systems, as well as provides an overview of the recent advances that have taken place in this arena. It is a 
well known fact that differences in gastric physiology such as, gastric pH and motility exhibit both intra as well as inter-subject variability 
demonstrating significant impact on gastric retention time and drug delivery behavior. Various attempts have been made to develop 
gastroretntive systems. Several approaches are currently utilized in the prolongation of the GRT, including floating drug livery system, 
swelling and expanding systems, polymeric Bioadhesive systems, high- density systems, modified-shape systems and other delayed gastric 
emptying devices. Floating dosage forms are emerging as a promising dosage forms. Floating dosage forms can be prepared as tablets, 
capsules by adding suitable ingredients as well as by adding gas generating gent. In this review various techniques used in floating dosage 
forms along with current and recent developments of stomach specific floating drug delivery systems for gastro retention are discussed. 
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INTRODUCTION 
Oral administration is the most convenient and preferred 
means of any drug delivery to the systematic circulation. 
Oral controlled release drug delivery have recently been 
of increasing interest in pharmaceutical field to achieve 
improved therapeutic advantages, such as ease of dosing 
administration, patient compliance and flexibility in 
formulation. Drugs that are easily absorbed from 
gastrointestinal tract (GIT) and have short half-lives are 
eliminated quickly from the systemic circulation. 
Frequent dosing of these drugs is required to achieve 
suitable therapeutic activity. To avoid this limitation, the 
development of oral sustained-controlled release 
formulations is an attempt to release the drug slowly into 
the gastrointestinal tract (GIT) and maintain an effective 
drug concentration in the systemic circulation for a long 
time
1
. After oral administration, such a drug delivery 
would be retained in the stomach and release the drug in 
a controlled manner, so that the drug could be supplied 
continuously to its absorption sites in the gastrointestinal 
tract (GIT). These drug delivery systems suffer from 
mainly two adversities: the short gastric retention time 
(GRT) and unpredictable short gastric emptying time 
(GET), which can result in incomplete drug release from 
the dosage form in the absorption zone (stomach or 
upper part of small intestine) leading to diminished 
efficacy of administered dose. To formulate a site-
specific orally administered controlled release dosage 
form, it is desirable to achieve prolong gastric residence 
time by the drug delivery. Prolonged gastric retention 
improves bioavailability, increases the duration of drug 
release, reduces drug waste, and improves the drug 
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solubility that are less soluble in a high pH 
environment
2
.  Also prolonged gastric retention time 
(GRT) in the stomach could be advantageous for local 
action in the upper part of the small intestine e.g. 
treatment of peptic ulcer, etc. Gastro retentive drug 
delivery is an approach to prolong gastric residence 
time, thereby targeting site-specific drug release in the 
upper gastrointestinal tract (GIT) for local or systemic 
effects. Gastro retentive dosage forms can remain in the 
gastric region for long periods and hence significantly 
prolong the gastric retention time (GRT) of drugs. Over 
the last few decades, several gastro retentive drug 
delivery approaches being designed and developed, 
including: high density (sinking) systems that is retained 
in the bottom of the stomach, low density (floating) 
systems that causes buoyancy in gastric fluids, 
mucoadhesive systems that causes bioadhesion to 
stomach mucosa, unfoldable, extendible, or swellable 
systems which limits emptying of the dosage forms 
through the pyloric sphincter of stomach, super porous 
hydrogel systems, magnetic systems etc. The current 
review deals with various gastro retentive approaches 
that have recently become leading methodologies in the 
field of site-specific orally administered controlled 
release drug delivery systems. 
BASIC PHYSIOLOGY OF GASTROINTESTINAL 
TRACT 
 
Figure 1: Anatomy of Stomach 
Anatomically the stomach is divided into three regions: 
Fundus, body and antrum (pylorus). 
The proximal part forms fundus and body act as 
reservoir for undigested materials where as the antrum is 
the main site for mixing motions and act as pump for 
gastric emptying by propelling actions
3
. Gastric 
emptying occurs during fasting as well as fed state.  
The patent of motility is however distinct in 2 states. 
During fasting state, inter digestive series of electrical 
events takes place, which cycles both through stomach 
and intestine every 2 to 3 hours. This is called the 
interdigestive myoelectric cycle or migrating 
myloelectric cycle (MMC), which is further divided 
into following 4 phases as described by Wilson and 
Washington (1989)
 4
. 
1. Phase I (basal phase) lasts from 40 to 60 minutes 
with contractions. 
2. Phase II (pre burst phase) lasts for 40 to 60 minutes 
with intermittent action potential and contractions. As 
the phase progress the intensity and frequency also 
increases gradually. 
3. Phase III (burst phase) last for 4 to 6 minutes. It 
includes intense and regular contractions for short 
period. It is due to this wave that all the undigested 
material is swept out of the stomach down to the small 
intestine. It is also known as the house keeper wave. 
4. Phase IV last for 0 to 5 minutes and occurs between 
phases III and I of 2 consecutive cycles. After the 
ingestion of a mixed meal, the pattern of contractions 
changes from fasted to that of fed state. This is also 
known as digestive motility pattern and comprises 
continuous contractions as in phase II of fasted state. 
These contractions results in reducing the size of food 
particles (to less than1mm) which are propelled toward 
the pylorus in a suspension form. During the fed state 
onset of MMC is delayed resulting in slowdown of 
gastric emptying rate. Scintigraphic studies determining 
gastric emptying rates revealed that orally administered 
controlled release dosage form are subjected to basically 
two complications that of short gastric residence time 
and unpredictable gastric emptying rate. 
                                         
Figure 2: Schematic representation of myloelectric cycle 
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Needs for gastric retention 
1) Drugs that are absorbed from the proximal part of 
the gastrointestinal tract (GIT).  
2) Drugs that are less soluble or are degraded by the 
alkaline pH they encounters at the lower part of 
GIT.  
3) Drugs that are absorbed due to variable gastric 
emptying time. Local or sustained drug delivery to 
the stomach and proximal Small intestine to treat 
certain conditions.  
4) Particularly useful for the treatment of peptic ulcers 
caused by H.Pylori Infections. 
Factors affecting gastric retention  
• Density of dosage form – Density of gastric fluid is 
reported to be 1.004gm/ml. The density of the dosage 
form should be less than this for buoyancy, so that it is 
retained in the stomach for a longer time. Dosage forms 
may have a high density in the beginning but float in the 
stomach due to reduction in density by swelling.  
• Composition of meal: Fats, particularly fatty acids 
inhibit gastric secretion and have a pronounced 
reductive effect on the rate of emptying. Proteins and 
starch are shown to have inhibitory effect on gastric 
emptying, though to a less extent. As the viscosity of the 
gastric fluids is increased, there is a corresponding 
decrease in the rate of emptying.  
• Caloric content: Gastric residence time can be 
increased by 4-10 hrs with a meal that is rich in proteins 
and fats.  
• Frequency of the food: - The gastric residence time 
can increase by >6 hrs when successive meals are given, 
compared with a single meal, due to low frequency 
MMC.  
• Size of dosage form: - In general it is known that 
indigestible solids > 1-2mm are retained in the stomach 
throughout the postprandial period, after which they are 
emptied by cyclical recurring brust of interdigestive 
gastric contractions. Many recent studies have shown 
that non disintegrating tablets as large as 7.0mm can be 
emptied from the human stomach during the 
postprandial period, while 13.0mm tablets are retained 
until arrival of subsequent sweeping ‘housekeeper 
waves’. This emphasizes the need for size enlargement 
of dosage forms in the stomach in order to prolong the 
gastric residence time.  
• Sex: - Generally females have a slower gastric 
emptying rate (4.6 1.2hrs) than males (3.40.6hr) 
regardless of weight, height and body surface area.  
• Body posture: - Gastric emptying is favored while 
standing and by lying on the right side since the normal 
curvature of the stomach provides a downhill path 
whereas lying on the left side or in supine position 
retards it.  
• Emotional state of subject: - The influence of 
emotional factors on gastric motility depending upon 
whether the emotional experience is of an aggressive or 
a depressive type.  
• Effect of drugs: - Drug that retard gastric emptying 
includes poorly soluble antacids (Aluminum hydroxide), 
anticholinergics (Atropine, Propantheline), narcotic 
analgesics (Morphine) and tricyclic antidepressants 
(Imipramine, amitryptiline), Metoclopramide, 
domperidom and cisapride (Anti emetics) stimulates 
gastric emptying.  
• Exercise: - Vigorous physical activity retards gastric 
emptying.  
• Disease states:-Diseases like gastroenteritis, gastric 
ulcer, pyloric stenosis, diabetes and hypothyroidism 
retard gastric emptying. Duodenal ulcer and 
hyperthyroidism promote gastric emptying rate.  
• Gastrointestinal pH: - Gastric emptying is retarded at 
low stomach pH and promoted at higher or alkaline pH. 
Chemicals that affect gastrointestinal pH also alter 
gastric emptying. The inhibitory effect of various acids 
on gastric emptying decreases with increase in 
molecular weight and is in the following order 
HCL>Acetic>lactic>tartaric>citric. With alkaline 
solutions, a low base concentration (1% NaHCO3) 
increases the gastric emptying rate more than the 1 of 
higher concentration (5%).  
Drugs suitable for GRDDS 
1) Drugs acting locally in the stomach   E.g. Antacids 
and drugs for H. Pylori viz., Misoprostol 
2) Drugs that are primarily absorbed in the stomach E.g. 
Amoxicillin 
3) Drugs that is poorly soluble at alkaline pH E.g. 
Furosemide, Diazepam, Verapamil 
4) Drugs with a narrow window of absorption E.g. 
Cyclosporine, Methotrexate, Levodopa, etc. 
5) Drugs which are absorbed rapidly from the GI tract. 
E.g. Metonidazole, tetracycline. 
6) Drugs that degrade in the colon. E.g. Ranitidine, 
Metformin HCl. 
7) Drugs that disturb normal colonic microbes E.g. 
antibiotics against Helicobacter pylori. 
Drugs unsuitable for GRDDS 
1. Drugs that have very limited acid solubility e.g. 
phenytoin etc. 
2. Drugs that suffer instability in the gastric 
environment e.g.  Erythromycin etc. 
3. Drugs intended for selective release in the colon. 
E.g. 5- amino salicylic acid and corticosteroids 
etc. 
Advantages 
1) Improves patient compliance.  
2) Bioavailability enhances despite first pass effect 
because fluctuations in plasma drug concentration is 
avoided, a desirable plasma drug concentration is 
maintained by continuous drug release  
3) Freedom from incompatibilities between drug and 
excipients especially with buffers.  
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4) Better therapeutic effect of short half life drugs can be 
achieved.  
5)  Gastric retention time is increased because of 
buoyancy.  
6) Site specific drug delivery to the stomach can be 
achieved.  
7)  Mask the unpleasant odor, taste of drugs and protect 
the drugs from the environment  
8) Freedom from incompatibilities between drugs and 
excipients especially the buffers and safe handling of 
toxic substances.  
9) Pulsatile release of antibiotics can alleviate evolution 
of the bacterial resistance. In the vaccine delivery, initial 
burst followed by delayed release pulses can mimic 
initial and boost injection, respectively.  
10) The local delivery system avoids systemic drug 
administration for local therapeutic effects and can 
reduce the related systemic side effects.  
11) The volatile drugs can be easily formulated as 
floating microspheres compared to other conventional 
dosage forms.  
Disadvantages 
1) These systems require a high level of fluid in the 
stomach for drug delivery to float however this can 
be overcome by using low density polymers.  
2) The release rate of the controlled release dosage 
form varies from a variety of factors like rate of food 
transit through the drug.  
3)  Potential toxicity due to loss of integrity of drugs.  
4) The dosage forms should be administered with more 
amount of water      (200-250ml).  
5) Some drugs present in the floating system causes 
irritation to gastric mucosa.  
6) These dosage forms should not be crushed or chewed 
APPROACHES FOR GASTRIC RETENTION 
To improve the retention of an oral dosage form in the 
stomach various approaches have been developed, e.g. 
floating systems, swelling and expanding systems, 
bioadhesive systems, altered density systems and other 
delayed gastric emptying devices. Floating Drug 
Delivery Systems (FDDS) or Hydrodynamically 
Balanced systems (HBS) have bulk density lower than 
gastric fluids and hence remain floating in the stomach 
for a prolonged period of time
5
. The drug is slowly 
released from the floating system at a desired rate 
without fluctuations in plasma drug concentration thus 
leading to an increase in the gastric residence time 
(GRT).After complete release of drug from the delivery 
system, the residual is expelled from the stomach. To 
localize delivery device within a cavity of body, 
bioadhesive systems are usually formulated. In these 
systems, bioadhesion is achieved by using bioadhesive 
polymers which adhere to the epithelial surface of 
gastrointestinal tract. The formation of hydrogen and 
electrostatic bonding at the mucus polymer interface 
leads to bioadhesion. Swellable systems are a type of 
gastro-retentive dosage forms which swell in the 
stomach to an extent that prevents its exit through the 
pyloric sphincter resulting in the retention of swellable 
system in the stomach for a prolonged period of time. 
Altered density gastro-retentive dosage forms includes 
systems that have density either greater or lower than 
the stomach contents leading to an increase in GRT and 
hence drug release for a prolonged time period.  
 
Figure 3: Different drug delivery system 
A) High Density Systems  
The density of the pellets must exceed that of normal 
stomach content (1.004 gm/cm2)
 6
. For preparing such 
formulations, drug can be coated on a heavy core or 
mixes with heavy inert materials such as barium sulfate, 
titanium dioxide, iron power and oxide. The weighed 
pellets can then be covered with a diffusion-controlled 
membrane. Other delayed emptying approaches of 
interest include same feeding of indigestible polymers or 
fatty acid salts that change the motility pattern of the 
stomach to a fed state, thereby decreasing the gastric 
emptying rate and permitting considerable prolongation 
of drug release. 
B) Swelling and expanding system  
One way to retain a dosage form in the stomach is by 
increasing its size. The stomach discharges its contents 
through the pylorus in to the intestine. If the dosage 
form can attain a size larger than that of the pylorus it 
can be retained in the stomach for a long time. Swelling 
type dosage forms are such that after swallowing these 
products swell to a extent that prevents their exit from 
the stomach through the pylorus as a result the dosage 
form is retained in the stomach for a long period of time. 
These systems may be referred to as “plug type system” 
since they exhibit a tendency to remain lodged at the 
pyloric sphincter.  
C) Bioadhesive Systems  
These systems are essentially based on bioadhesive 
polymers, which adhere to the mucin and / or epithelial 
surface. Bioadhesive polymers can bind mucus as well 
as non-mucus membranes. If bioadhesion is restricted to 
mucosal surface it is called mucoadhesion. Non-specific 
bioadhesive systems bind to mucin and epithelial 
surface by non-specific interaction between polymer 
particle and intestinal surfaces
7
. Specific bioadhesive 
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systems are designed by attaching a ligand to polymer 
particles, the ligand then recognizes and attaches to a 
specific area of the mucosal surface. Mucoadhesive 
controlled release systems increase the effectiveness of 
the drug by maintaining the drug concentration in 
therapeutic level, inhibiting the dilution of drugs in body 
fluids, and allowing targeting and localization of drugs 
at specific site. The duration of contract and intimacy 
between polymer-drug particles and mucosal surface is 
increased by mucoadhesion.  
Lecithin is the most commonly used ligand for specific 
bioadhesion. Nonspecific bioadhesion mainly depends 
on the nature of polymer used for the system. Various 
polymers such as poly (acrylates), poly (lactic acid) 
chitosan, alginates, polystyrenes and sodium 
hyaluronate are reportedly bioadhesive in nature. 
D) Floating Drug Delivery systems and its 
mechanism: 
Davis in 1968 first described the FDDS. Floating drug 
delivery systems (FDDS) have bulk density lesser than 
gastric fluids, so they remain buoyant in the stomach 
without affecting the gastric emptying rate for a 
prolonged period of time. While the system is floating 
on the gastric contents, the drug is released slowly at the 
desired rate from the system. After release of drug, the 
residual system is emptied from the stomach. This 
results in an increased GRT and a better control of the 
fluctuations in plasma drug concentration. However, 
besides a minimal gastric content needed to allow the 
proper achievement of the buoyancy retention principle, 
a minimal level of floating force (F) is also required to 
keep the dosage form reliably buoyant on the surface of 
the meal. To measure the floating force kinetics, a novel 
apparatus for determination of resultant weight has been 
reported in the literature. The apparatus operates by 
measuring continuously the force equivalent to F (as a 
function of time) that is required to maintain the 
submerged object. The object floats better if F is on the 
higher positive side as shown in figure. This apparatus 
helps in optimizing FDDS with respect to stability and 
durability of floating forces produced in order to prevent 
the drawbacks of unforeseeable intragastric buoyancy 
capability variations. 
 F = F buoyancy – F gravity   = (Df – Ds) gv 
  Where, F= total vertical force, Df = fluid density, 
   Ds= object density, v = volume an 
   g =acceleration due to gravity
 
 
Figure 4: Mechanism of floating systems, GF=Gastric fluid 
 
CLASSIFICATION OF FLOATING SYSTEM
8
 
Based on the mechanism of floating, the floating drug 
delivery systems are of following types: 
A) Non effervescent floating dosage form 
These dosage forms use a gel forming or swellable 
cellulose type of hydrocolloids, polysaccharides and 
matrix forming polymers like polycarbonates, 
polymethacrylate and polystyrene. The formulation is 
done by mixing the drug and the gel-forming 
hydrocolloid, after oral administration of this dosage 
form swells while in contact with gastric fluids attains 
bulk density of <1. The buoyancy of dosage form was 
attained due to the air entrapment in to the swollen gel 
like structure acts as a reservoir and allows sustained 
release of drug through the gelatinous mass. 
a. Colloidal gel barrier systems 
b. Micro porous compartment systems 
c. Alginate beads 
B) Effervescent floating dosage forms  
These are the matrix types of systems which are 
prepared by using swellable like methyl cellulose, 
HPMC and chitosan based polymers as well as various 
effervescent compounds like Sodium carbonate, 
Calcium carbonate, Tartaric acid and Citric acid. They 
are formulated in such a way that when in contact with 
the acidic gastric contents liberation of CO2 takes place 
and gets entrapped in to the swollen hydrocolloids which 
provides buoyancy to the dosage forms. 
      i. Volatile liquid containing systems 
     ii. Gas generating systems 
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POLYMERS AND OTHER INGREDIENTS USED 
Numerous polymers and carriers have been utilized for 
fabrication and to control the drug release in gastric 
environment
10
. The polymers used in the preparation of 
floating beads are;  
1. Synthetic polymers.  
2. Natural polymers  
i) Polymers: The following polymers used to 
preparations of floating drugs: HPMC K4 M, Calcium 
alginate, Eudragit S100 Eudragit RL, Propylene foam, 
Eudragit RS, ethyl cellulose, poly methyl methacrylate, 
Methocel K4M, Polyethylene oxide, % Cyclodextrin, 
HPMC 4000, HPMC 100, CMC, Polyethylene glycol, 
polycarbonate, PVA, Polycarbonate, Sodium alginate, 
HPC-L, HPC, Eudragit S, HPMC, Metolose S.M. 100, 
PVP, HPCH, HPC-M, HPMC K15, Polyox, HPMC K4, 
Acrylic polymer E4 M and Carbopol. 
ii) Inert fatty materials (5 - 75%): Edible, inert fatty 
materials having a specific gravity of less than one can 
be used to decrease the hydrophilic property of 
formulation and hence increase buoyancy. E.g. 
Beeswax, fatty acids, long chain fatty alcohols, 
Gelucires® 39/01 and 43/01. 
iii) Effervescent agents: Sodium bicarbonate, citric 
acid, tartaric acid, Di-SGC (Di-Sodium Glycine 
Carbonate, CG (Citroglycine). 
iv) Release rate accelerants (5 - 60%): eg. lactose, 
mannitol. 
v) Release rate retardants (5 - 60%): eg. Dicalcium 
phosphate, talc, magnesium stearate 
vi) Buoyancy increasing agents (upto 80%): eg. Ethyl 
cellulose 
vii) Low density material: Polypropylene foam powder 
(Accurel MP 1000®).    
Role of Polymers in Floating drug delivery  
The currently available polymer-mediated non 
effervescent and effervescent FDDS, designed on the 
basis of delayed gastric emptying and buoyancy 
principles, appear to be an effective and rational 
approach to the modulation of controlled oral drug 
delivery. This is evident from the number of commercial 
products and a myriad of patents issued in this field
11
. 
The FDDS become an additional advantage for drugs 
that are absorbed primarily in the upper segments of GI 
tract, i.e., the stomach, duodenum and jejunum. Some of 
the unresolved, critical issues related to the rational 
development of FDDS include:-  
(1) The quantitative efficiency of FDDSs in the fasted 
and fed states; 
(2) The role of buoyancy in enhancing GRT of FDDS; 
and  
(3) The correlation between prolonged GRT and SR/PK 
characteristics.
  
Table 1:  Types of Polymers with Examples 
Polymer Sub Type Examples 
Synthetic 
polymer 
Biodegradable Lactides, glycosides and their co polymers. Poly alkyl 
cyanoacrylates, polyanhydrides 
Non-biodegradable Polymethyl methacrylate, Acrolin, Glycidyl 
methacrylate, epoxy polymers 
Natural Proteins Albumin, Gelatin, Collagen 
Carbohydrates Agarose, carragenan, Chitosan, starch 
Chemically modified carbohydrates Poly dextran, poly starch 
 
Table 2: Polymers and Their Applications 
Polymer Application 
Modified starch, HPMC, Carbopol 974p Slower release of drug 
Ethyl cellulose Controlled release for longer period of time 
PLGA, chitosan Vaccine delivery 
Chitosan coated PLGA polymers Targeted drug delivery 
Polyvinyl alcohol, polyacrylidine Adsorption of harmful substance in blood 
 
Table 3: Polymers used in preparations of GRDDS 
Polymers HPMC 4000, HPMC 100, HPMC K4M, CMC, PVA, Calcium     alginate, Carbopol, 
Ethyl cellulose,Eudragit RS and RL, acrylic polymer 
Buoyancy increasing agents     Ethyl cellulose 
Release rate accelerants Mannitol, Lactose 
Release rate retardants Magnesium Stearate, Dicalcium phosphate, Talc 
Low density materials Polypropylene foam powder 
Inert fatty materials Fatty acids , Bees wax, 
Effervescent agents Tartaric acid, Citric acid, Sodium bicarbonate, Citroglycine 
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METHODS OF PREPARATION OF FLOATING 
BEADS 
1) Solvent evaporation method 
Floating multiparticulate dosage form was prepared by 
solvent diffusion and evaporation methods to create the 
hollow inner core. The polymer is dissolved in an 
organic solvent and the drug is either dissolved or 
dispersed in the polymer solution. The solution 
containing the drug is then emulsified into an aqueous 
phase containing polyvinyl alcohol to form oil in water 
emulsion. After the formation of a stable emulsion, the 
organic solvent is evaporated either by increasing the 
temperature under pressure or by continuous stirring. 
The solvent removal leads to polymer precipitation at 
the o/w interface of droplets, forming cavity and thus 
making them hollow to impart the floating properties. 
The polymers studied for the development of such 
systems include Cellulose acetate, Chitosan, Eudragit, 
Acrycoat, Methocil, Polyacrylates, Polyvinyl acetate, 
Carbopol, Agar, Polyethylene oxide and 
Polycarbonates
12
. Furthermore, a novel multi-particulate 
gastro-retentive drug delivery system based on low-
density foam powder has been proposed and its 
performance demonstrated in and. Floating micro 
particles consisting of Polypropylene foam powder, 
Verapamil HCl (as the model drug) and Eudragit RS, 
Ethylcellulose or Poly (methyl methacrylate) (PMMA) 
were prepared with an oil-inwater solvent 
extraction/evaporation method. The drug and release-
rate-controlling polymer were dissolved in Methylene 
chloride. Polypropylene foam powder was then 
dispersed within this organic phase. The resulting 
suspension was subsequently emulsified into an external 
aqueous Poly (vinyl alcohol) solution and agitated with 
a stirrer to allow microparticle formation. The 
microparticles were separated by being sieved, washed 
with water and dried in a desiccator; they were irregular 
in shape and highly porous. Importantly, the drug 
encapsulation efficiency was high and almost 
independent of the theoretical loading of the system. In 
all cases, good in-and floating behavior was observed. 
Interestingly, a broad spectrum of release patterns could 
be obtained with the investigated formulations. Further 
studies focused on the development of an improved 
preparation method for this type of low density, foam-
based, floating micro-particle and also on the 
demonstration of the system’s performances inand. 
Major advantages of the suggested novel preparation 
technique include short processing times, no exposure of 
the ingredients to high temperatures, the ability to avoid 
toxic organic solvents and high encapsulation 
efficiencies (close to 100%). Floating micro-particles 
consisting of Polypropylene foam powder, model drug 
(Chlorpheniramine maleate, Diltiazem HCl, 
Theophylline or Verapamil HCl) and a second polymer 
[Eudragit RS or Poly(methyl methacrylate)] were 
prepared by soaking microporous foam particles with an 
organic solution of the drug and polymer and 
subsequent drying Good in- and floating behavior was 
observed in most cases and a broad variety of drug 
release patterns could be achieved by varying the drug 
loading and type of second polymer
13
. In addition, the 
low density micro-particles could be compressed into 
rapidly disintegrating tablets, providing an easily 
administrable oral dosage form. 
 
 
Figure 5: Schematic presentation of the preparation of floating micro-particles based on low-density foam powder, 
using (a) The solvent evaporation method or (b) The soaking method. 
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2) Ionotropic gelation method 
Ionotropic gelation is based on the ability of 
polyelectrolyte to cross link in the presence of counter 
ions to form beads. Since, the use of Alginates, Gellan 
gum, Chitosan and Carboxymethyl cellulose for the 
encapsulation of drug and even cells, ionotropic gelation 
technique has been widely used for this purpose
14
. The 
natural polyelectrolyte inspite, having property of 
coating on the drug core and acts as release rate 
retardants contains certain anions on their chemical 
structure. These anions forms meshwork structure by 
combining with the polyvalent cations and induce 
gelation by binding mainly to the anion blocks. The 
hydrogel beads are produced by dropping a drug-loaded 
polymeric solution into the aqueous solution of 
polyvalent cations. Biomolecules can also be loaded into 
these beads under mild conditions to retain their three 
dimensional structure. The schematic representation of 
ionotropic gelation method is shown in figure. El-Gibaly 
et al developed floating (F) microcapsules containing 
melatonin (MT), prepared by the ionic interaction of 
Chitosan and negatively charged surfactant, Sodium 
dioctyl sulfosuccinate (DOS). The characteristics of the 
floating microcapsules generated compared with the 
conventional non-floating (NF) microspheres 
manufactured from Chitosan and Sodium 
tripolyphosphate (TPP) were also investigated. Talukder, 
R. et al developed floatable multiparticulate system with 
potential for intra gastric sustained drug delivery. Cross-
linked beads were made by using calcium and low 
methoxylated pectin (LMP), which are an anionic 
polysaccharide, Calcium, LMP and Sodium alginate. 
Beads were dried separately in an air convection type 
oven at 40
o
C for 6 hours and in freeze dryer to evaluate 
the changes in bead characteristics due to process 
variability
15
. Riboflavin (B-2), Tetracycline (TCN) and 
Methotrexate (MTX) were used as model drugs for 
encapsulation. Ionic and nonionic excipients were added 
to study their effects on the release profiles of the beads.
 
                              
                                                        Figure 6: Ionotropic gelation method 
Evaluation Tests for Floating Beads 
1. Angle of Repose: 
 Angle of repose helps to evaluate powder flowability by 
assessing interparticulate friction. In general, the higher 
is the angle of repose poor is the flowability of powder
16
. 
The angle of repose of each powder blend was 
determined by glass funnel method, using following 
equation, 
      
 
 
 
Where,   - angle of repose, h - height of pile above the 
flat surface, r - radius of the circle formed by the powder 
blend.   
2. Bulk Density: 
It is ratio of mass to bulk volume. Bulk density may 
influence dissolution and other properties and depends 
on the particle size, shape and tendency of particles to 
adhere together. Bulk density of formulated beads was 
determined by taking a known mass of beads in a 5 ml 
graduated measuring cylinder. The cylinder was dropped 
three times from a height of one inch at an interval of 
two seconds. The bulk density was calculated by 
following equation, 
             
                    
           
 
3. Tapped density: 
Tapped density helps to determine packing geometry 
and flowability. Tapped density is the volume of powder 
determined by tapping using measuring cylinder 
containing weighed amount of sample. Tapped density 
of beads was calculated by following equation, 
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4. Carr’s compressibility index: 
This is an important property in maintaining uniform 
weight. It is calculated using following Equation, 
             
                           
              
      
Table 4: Carr’s compressibility index: 
Carr’s (compressibility index) Flowability 
5-15 Excellent 
12-16 Good 
18-21 Fair to passable 
23-35 Poor 
33-38 Very poor 
>40 Extremely poor 
 
5. Hausner’s ratio: 
Hausner’s ratio less than 1.25 indicates good flow and 
greater than 1.5 indicates poor flow whereas between 
1.25 and 1.5 indicates glidant normally improves flow. 
Hausner’s ratio can be calculated by formula, 
                
              
            
 
6. Morphology study: 
Scanning Electron Microscopy (SEM) was performed to 
characterize the surface of formed beads. Beads were 
mounted directly onto the sample stub and coated with 
gold ion and analyze for surface morphology. 
7. Particle size analysis: 
The particle size of drug loaded formulations were 
measured by an optical microscope fitted with calibrated 
ocular and stage micrometer and particle size 
distribution was calculated. 50 particles in five different 
fields were examined. 
8. Determination of Percentage yield 
The prepared beads were collected and weighed. The 
measured weight was divided by the total amount of all 
non-volatile components, which were used for the 
preparation of the beads. 
                 
                        
                             
      
9. Drug Entrapment Efficiency 
Beads equivalent to 100 mg of the drug were taken for 
evaluation. The amount of drug entrapped was estimated 
by crushing the beads and extracting with aliquots of 
0.1N HCl repeatedly. The extract was transferred to a 
100 ml volumetric flask and the volume was made up 
using 0.1N HCl
17
. The solution was filtered and the 
absorbance was measured at suitable wavelength against 
appropriate blank. The amount of drug entrapped in the 
beads was calculated by the following formula, 
                            
                               
                                
      
10. In vitro buoyancy study 
Beads (300mg) were spread over the surface of a USP 
XXIV dissolution apparatus type II filled with 900 ml of 
0.1 N HCl containing 0.02% Tween 80. The medium 
was agitated with a paddle rotating at 100 rpm for 12 hr. 
The floating and the settled portions of beads were 
recovered separately. The beads were dried and 
weighed. Buoyancy percentage was calculated as the 
ratio of the mass of the beads that remained floating and 
the total mass of the beads.  
           
  
     
      
Where, 
Qf = Weight of the floating Beads  
Qs = Weight of settled Beads 
11. In-vitro drug release study 
The drug release study from beads is performed using 
USP dissolution apparatus Type I in 900 ml of 0.1 N 
HCl dissolution media (pH- 1.2) at 100 rpm and 37°C. 2 
ml sample was withdrawn at 1 hr. time interval for 12 hr. 
and same volume of fresh medium was replaced to 
maintained sink condition. Withdrawn samples were 
assayed spectrophotometrically at suitable wavelength. 
The drug release was analyzed by UV spectro-
photometer. 
12. Determination of Moisture Content 
The formulations were subjected to moisture content 
study by using an IR moisture balance by placing the 
beads at 60 °C for 10 min. 
13. SEM of floating beads 
Morphological characterization of the floating alginate 
beads is done by taking scanning electron micrograph 
(Model Jeol JSM-5200)
 18
. Cross-sectional views are 
obtained by cutting the bead with a razor blade. The 
samples were coated to 200 Aº thickness with gold- 
palladium prior to microscopy. A working distance of 20 
nm, a tilt of 0º and accelerating voltage of 15 KV were 
the operating parameters. Photographs were taken within 
the range of 50- 500 magnifications. 
Application of floating drug delivery systems
19
 
Floating drug delivery offers several applications for 
drugs having poor bioavailability because of the narrow 
absorption window in the upper part of the 
gastrointestinal tract. It retains the dosage form at the 
site of absorption and thus enhances the bioavailability. 
These are summarized as follows: 
1. Sustained drug delivery: FDDS can remain in the 
stomach for long periods and hence can release the drug 
over a prolonged period of time. The problem of short 
gastric residence time encountered with an oral CR 
formulation hence can be overcome with these systems. 
These systems have a bulk density of <1 as a result of 
which they can float on the gastric contents. These 
systems are relatively large in size and passing from the 
pyloric opening is prohibited. E.g. Sustained release 
floating capsules of Nicardipine Hydrochloride 
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2. Site-specific drug delivery: These systems are 
particularly advantageous for drugs that are specifically 
absorbed from stomach or the proximal part of the small 
intestine. E.g. Riboflavin and Furosemide  
3. Absorption enhancement: Drugs that have poor 
bioavailability because of site specific absorption from 
the upper part of the gastrointestinal tract are potential 
candidates to be formulated as floating drug delivery 
systems, thereby maximizing their absorption. 
4. Reduced fluctuations of drug concentration: 
Continuous input of the drug following Controlled 
Release administration produces blood drug 
concentrations within a narrower range compared to the 
immediate release dosage forms. Thus, fluctuations in 
drug effects are minimized and concentration dependent 
adverse effects that are associated with peak 
concentrations can be prevented. This feature is of 
special importance for drugs with a narrow therapeutic 
index.  
5. Improved selectivity in receptor activation: 
Minimization of fluctuations in drug concentration also 
makes it possible to obtain certain selectivity in the 
elicited pharmacological effect of drugs that activate 
different types of receptors at different concentrations. 
6. Maintenance of Constant Blood Level: These 
systems provide an easy way of maintaining constant 
blood level with an ease of administration and better 
patient compliance. 
Recent advances in stomach specific floating dosage 
forms: 
Sungthongjeen et al have prepared a floating multilayer 
coated tablets based on gas formation. The system 
consists of a drug containing core tablet coated with a 
protective layer (hydroxyl propyl methyl cellulose), a 
gas forming layer (sodium bicarbonate) and a gas-
entrapped membrane, respectively. Eudragit RL 30D 
was chosen as a gas-entrapped membrane due to its high 
flexibility and high water permeability
20
. The obtained 
tablets enabled to float due to the CO2 gas formation 
and the gas entrapment by polymeric membrane. The 
effect of formulation variables on floating properties and 
drug release was investigated. The floating tablets using 
direct compressed cores had shorter the time to float and 
faster drug release than those using wet granulated cores. 
The increased amount of a gas forming agent did not 
affect time to float but increased the drug release from 
the floating tablets, while increasing the coating level of 
gas entrapped membrane increased the time to float 
(more than 8 hours) and slightly retarded, but sustained 
drug release. Rajnikanth et al have developed a floating 
in situ gelling system of clarithromycin (FIGC) using 
gellan as gelling polymer and calcium carbonate as 
floating agent for potentially treating gastric ulcers, 
associated with Helicobacter pylori (H.pylori). Gellan 
based FIGC was prepared by dissolving varying 
concentrations of gellan in deionized water, to which 
varying concentrations of the drug and sucralfate were 
dispersed well
30-35
. The addition of sucralfate to the 
formulation significantly suppressed the degradation of 
clarithromycin at low pH. FIGC showed a significant 
anti H. pylori effect than that of clarithromycin 
suspension
25
. The in situ gel formulation with sucralfate 
cleared H.pylori more effectively than that of 
formulation without sucralfate. In addition, the required 
amount of clarithromycin for eradication of H.pylori was 
found to be less from FIGC than from the corresponding 
clarithromycin suspension. It was concluded that 
prolonged gastrointestinal residence time and enhanced 
clarithromycin stability resulting from the floating in situ 
gel of clarithromycin might contribute better for 
complete clearance of H. pylori than the corresponding 
clarithromycin suspension
39-42
. 
GRDDS-The Industrial Perspective  
Pharmacotherapy of various disease states can be 
amended by drug repurposing through GRDDS. 
Assessment of the effect of the fed and fasted condition 
on product performance should be necessary during 
initial development phases
26
. Dual working technology 
would be a possible way to overcome drawbacks 
associated with different GRDDS. Before development 
of a drug product, the principles of scale up and process 
validation must be considered to improve the quality and 
market availability of GRDDS. Knowledge of all 
regulatory aspects will help to deliver a product to the 
market within a reasonable timeframe and in a cost-
effective manner. Varieties of investigations have been 
done that lead to development of various GRDDS. 
However, only few can make way to market. These 
technologies show excellent in vitro results but fail to 
give desirable in vivo performance. Mucoadhesive and 
floating technologies are getting substantial attention 
and most of the drug products available in the market are 
based on the principle of these technologies. In 
consequence, dual working systems based on 
mucoadhesive and floating principles have more 
potential to increase industrial implementation of 
GRDDS and can improve the in vivo performance of the 
active moiety
27
. Furthermore, combination of 
mucoadhesion technology with floating technology can 
ameliorate loopholes associated with floating technology 
like floating lag time. In future, some more gastro-
retentive technologies can be combined to improve the 
gastric retention and to reduce the associated drawbacks 
GIP. Thus, market appearance of GRDDS can be 
improved by opting an appropriate drug and delivery 
system with incorporating all the relevant quality 
attributes
28
. TABLE below gives an overview of 
technologies adopted by pharmaceutical companies to 
formulate GRDDS. 
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TABLE 5: Technologies adopted for GRDDS 
Technology  Company  Product  Active pharmaceutical 
ingredient  
Bioadhesive tablets  Lupin, India  Xifaxan  Rifaximin  
Floating liquid alginate 
preparation  
Pierre Fabre Medicament, 
France  
Topalkan  
 
Aluminium magnesium 
antacid  
Polymer-based swelling 
technology: AcuForm_  
Depomed, Inc., USA  
 
Gabapentin GR  
 
Gabapentin  
 
Coated multi-layer floating and 
swelling system  
Sun Pharma, India  
 
Baclofen GRS  
 
Baclofen  
 
 
CONCLUSION  
The identification of new diseases and the resistance 
shown towards the existing drugs felt the need for the 
introduction of new therapeutic molecules
35
. In 
response, a large number of chemical entities have been 
introduced, of which some have absorption all over the 
GIT and others have absorption windows in the upper 
part of the small intestine. The drugs that are required 
for local action in the GIT require a specialized delivery 
system which has been achieved by FDDS. A number of 
FDDS have been developed such as single and multiple 
unit HBS, single and multiple unit gas generating 
systems, hollow microspheres and raft forming systems. 
Development of sustained release formulations is 
advantageous in providing prolonged gastric retention 
and increased efficacy of the dosage forms
40-44
. The 
floating behavior of the low density drug delivery 
systems could successfully be combined with accurate 
control of the drug release patterns in order to boast 
accurate bioavailability. Hence further studies are 
needed in this regard in order to encompass effective 
drug delivery systems. 
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